Brian Serumaga, MPH, PhD: No financial relationships to disclose
Brenda S. Jensen, CPhT, CNMT, MBA: Compounding Pharmacies: Consultant (Ongoing)
Straight from the source itself, representatives from USP and NIOSH will review the latest updates to the USP compounding standards <795> and <797> and describe key themes from stakeholder engagement during the development of these chapters over the last 10 years. You’ll also get the latest updates to the NIOSH list of hazardous drugs, as well as information on handling these drugs throughout the health system. Finally, the session will provide examples of common scenarios, implementation strategies and other best practices.
Learning Objectives:
Explain the process for creating or revising a USP standard
Describe the background of the revisions for USP 〈795〉 and USP 〈797〉
Identify key aspects of the revisions to USP 〈795〉 and USP 〈797〉